Compare JOE & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | DYN |
|---|---|---|
| Founded | 1936 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.4B |
| IPO Year | N/A | 2020 |
| Metric | JOE | DYN |
|---|---|---|
| Price | $67.37 | $16.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $39.94 |
| AVG Volume (30 Days) | 182.7K | ★ 2.1M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 53.79 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $488,689,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.71 | ★ N/A |
| Revenue Growth | ★ 26.89 | N/A |
| 52 Week Low | $40.19 | $6.36 |
| 52 Week High | $68.48 | $25.00 |
| Indicator | JOE | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 69.64 | 44.74 |
| Support Level | $64.42 | $16.52 |
| Resistance Level | $67.35 | $19.39 |
| Average True Range (ATR) | 1.60 | 0.98 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 99.46 | 38.94 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.